Grayken Center for Addiction, Boston Medical Center, Boston, MA, USA.
Section of General Internal Medicine, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA, USA.
Subst Use Addctn J. 2024 Oct;45(4):771-776. doi: 10.1177/29767342241249386. Epub 2024 May 12.
People who experience a nonfatal opioid overdose and receive naloxone are at high risk of subsequent overdose death but experience gaps in access to medications for opioid use disorder. The immediate post-naloxone period offers an opportunity for buprenorphine initiation. Limited data indicate that buprenorphine administration by emergency medical services (EMS) after naloxone overdose reversal is safe and feasible. We describe a case in which a partnership between a low-barrier substance use disorder (SUD) observation unit and EMS allowed for buprenorphine initiation with extended-release injectable buprenorphine after naloxone overdose reversal.
A man in his 40's with severe opioid use disorder and numerous prior opioid overdoses experienced overdose in the community. EMS was activated and he was successfully resuscitated with intranasal naloxone, administered by bystanders and EMS. He declined emergency department (ED) transport and consented to transport to a 24/7 SUD observation unit. The patient elected to start buprenorphine due to barriers attending opioid treatment programs daily. His largest barrier was unsheltered homelessness. His severe opioid withdrawal symptoms were successfully treated with 16/4 mg sublingual buprenorphine/naloxone and 300 mg extended-release injectable buprenorphine (XR-buprenorphine), without precipitated withdrawal. Two weeks later, he reported no interval fentanyl use.
We describe the case of a patient successfully initiated onto XR-buprenorphine in the immediate post-naloxone period via a partnership between an outpatient low-barrier addiction programs and EMS. Such partnerships offer promise in expanding buprenorphine access and medication choice, particularly for the high-risk population of patients who decline ED transport.
经历非致命性阿片类药物过量并接受纳洛酮治疗的人随后有很高的阿片类药物过量死亡风险,但获得阿片类药物使用障碍治疗药物的机会有限。纳洛酮逆转后即刻提供了开始使用丁丙诺啡的机会。有限的数据表明,在纳洛酮逆转阿片类药物过量后,由急救医疗服务(EMS)给予丁丙诺啡是安全且可行的。我们描述了一个案例,在这个案例中,一个低障碍物质使用障碍(SUD)观察单位和 EMS 之间的合作使得在纳洛酮逆转阿片类药物过量后,可以使用丁丙诺啡延长释放注射剂来开始丁丙诺啡治疗。
一名 40 多岁的男子患有严重的阿片类药物使用障碍和多次阿片类药物过量,在社区中发生了过量。EMS 被激活,他被成功地用鼻内纳洛酮复苏,纳洛酮由旁观者和 EMS 给予。他拒绝前往急诊部(ED),并同意被送往 24/7 SUD 观察单位。由于每天参加阿片类药物治疗项目的障碍,该患者选择开始使用丁丙诺啡。他最大的障碍是无家可归。他严重的阿片类药物戒断症状通过给予 16/4mg 舌下丁丙诺啡/纳洛酮和 300mg 丁丙诺啡延长释放注射剂(XR-丁丙诺啡)得到了成功治疗,没有出现戒断症状。两周后,他报告没有间隔使用芬太尼。
我们描述了一名患者通过门诊低障碍成瘾治疗计划和 EMS 之间的合作,在纳洛酮逆转后即刻成功开始使用 XR-丁丙诺啡的案例。这种合作有希望扩大丁丙诺啡的获取途径和药物选择,特别是对于拒绝 ED 转运的高危人群患者。